drugset / Trial / NCT04469699
Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma
Phase 2
Terminated
30 enrolled
University Hospital Muenster
Deutsche Krebshilfe e.V., Bonn (Germany) · collabLifePhotonic GmbH · collabmedac GmbH · collabphotonamic GmbH & Co. KG · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
In this multicenter, randomized, non-blinded trial the efficacy and safety of stereotactical photodynamic therapy with 5-aminolevulinic acid will be investigated in 106 patients with recurrent glioblastoma.
Timeline
- Start
- 2021-04-12
- Primary completion
- 2025-01-30
- Completion
- 2025-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aminolevulinic Acid | Diagnostic / imaging agent | 20 mg/kg | Oral |